Synlogic achieves research milestone, earns $2.5M milestone payment

Synlogic (SYBX) announced that it has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million due under its collaboration agreement with Roche (RHHBY) for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease. “The field of IBD presents a clear need for therapeutic innovation, and there is a compelling fit with the disease biology and the locally acting, gut-restricted approach of Synthetic Biotics,” said Mylene Perreault, Ph.D., Vice President and Head of Research at Synlogic. “We are proud of the joint research team’s progress and accomplishments achieved through this collaboration, and our contribution towards a new potential biotherapeutic for IBD.”